文献速递泌尿男性生殖肿瘤支持与姑息治疗

抑制组蛋白去乙酰化酶以逆转血管生成抑制剂耐药:阿贝西诺他联合帕唑帕尼治疗晚期实体瘤的I期研究

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
PubMed 文献 · J Clin Oncol · 2017-02-21

这项I期试验评估组蛋白去乙酰化酶抑制剂阿贝西诺他联合帕唑帕尼表观遗传调控VEGF和缺氧诱导因子以增强疗效并逆转耐药。51例患者入组(肾细胞癌22例,59%既往接受过≥1线VEGF靶向治疗)。方案B下推荐II期剂量为阿贝西诺他45 mg/m2每日两次联合帕唑帕尼800 mg/d,总体客观缓解率21%,肾细胞癌亚组27%,中位缓解持续时间9.1个月,在帕唑帕尼难治患者中观察到持久缓解。

要点

  • 推荐II期剂量:阿贝西诺他45 mg/m2每日两次(方案B)联合帕唑帕尼800 mg/d
  • 总体客观缓解率21%,肾细胞癌亚组27%,中位缓解持续时间9.1个月
  • 10例帕唑帕尼难治患者中7例(70%)观察到持久肿瘤消退

核心结论

  • 阿贝西诺他与帕唑帕尼联合耐受良好,可实现延长暴露,并在帕唑帕尼及其他VEGF抑制剂难治肿瘤中显示出有前景的持久缓解,支持表观遗传介导的治疗耐药逆转。

研究设计与样本

  • I期试验,采用3+3剂量递增设计,在所有实体瘤中进行剂量递增,随后在肾细胞癌中进行剂量扩展;共入组51例患者,其中肾细胞癌22例,30例(59%)既往接受过≥1线VEGF靶向治疗。
  • 帕唑帕尼每日一次,第1至28天给药;阿贝西诺他口服每日两次,方案A为第1至5天、第8至12天、第15至19天给药,方案B为第1至4天、第8至11天、第15至18天给药。

主要发现

  • 方案A观察到5例剂量限制性毒性,包括疲乏(n=2)、血小板减少(n=2)和AST/ALT升高(n=1);方案B观察到1例剂量限制性毒性(AST/ALT升高)。
  • ≥3级相关不良事件包括疲乏(16%)、血小板减少(16%)和中性粒细胞减少(10%)。
  • 总体客观缓解率为21%,肾细胞癌亚组为27%;中位缓解持续时间为9.1个月(1.2至>49个月)。
  • 8例患者(16%)疾病持久控制>12个月;10例帕唑帕尼难治患者中7例(70%)观察到持久肿瘤消退,包括1例肾细胞癌患者缓解持续>3.5年。
  • 外周血组蛋白乙酰化和HDAC2基因表达与持久缓解相关。

关键数值与推荐

  • 推荐II期剂量为阿贝西诺他45 mg/m2每日两次按方案B给药联合帕唑帕尼800 mg/d。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance. Patients and Methods Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12, and 15 to 19 (schedule A) or on days 1 to 4, 8 to 11, and 15 to 18 (schedule B). Dose escalation (3 + 3 design) in all solid tumors was followed by dose expansion in renal cell carcinoma (RCC). Results Fifty-one patients with RCC (N = 22) were enrolled, including 30 (59%) with one or more lines of prior VEGF-targeting therapy. Five dose-limiting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were observed with schedule A; one dose-limiting toxicity was observed (elevated AST/ALT) was observed with schedule B. Grade ≥ 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%). The recommended phase II dose was established as abexinostat 45 mg/m2 twice a day administered per schedule B plus pazopanib 800 mg/d. Objective response rate was 21% overall and 27% in the RCC subset. Median duration of response was 9.1 months (1.2 to > 49 months). Eight patients (16%) had durable control of disease for > 12 months. Durable tumor regressions were observed in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with ongoing response > 3.5 years. Peripheral blood histone acetylation and HDAC2 gene expression were associated with durable response to treatment. Conclusion Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Thomas S, Pawlowska N, et al. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017. PMID: 28221861. doi:10.1200/JCO.2016.70.5350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。